AREPANRIX H5N1 DIN 02401886
Status: Marketed
Holder: ID BIOMEDICAL CORPORATION OF QUEBEC
Health Canada record
| Active ingredient(s) | HAEMAGGLUTININ-STRAIN A (H5N1) 3.75 MCG |
|---|
| Dosage form | Emulsion |
|---|
| Route | Intramuscular |
|---|
| Schedule | SCHEDULE D |
|---|
| Class | Human |
|---|
| ATC | J07BB02 INFLUENZA, INACTIVATED, SPLIT VIRUS OR SURFACE ANTIGEN |
|---|
| Original market date | 21-Mar-2025 |
|---|
| Current status date | 21-Mar-2025 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
ID Biomedical Corporation of Quebec — licence 101287, currently licensed, last inspection rating C (2026-03-04).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing HAEMAGGLUTININ-STRAIN A (H5N1)
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02510561 | FOCLIVIA | SEQIRUS UK LIMITED | Suspension | HAEMAGGLUTININ-STRAIN A (H5N1) 7.5 MCG | Approved |
| 02510588 | FOCLIVIA | SEQIRUS UK LIMITED | Suspension | HAEMAGGLUTININ-STRAIN A (H5N1) 7.5 MCG | Approved |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 34570 | 2024-12-03 | Supplement to a New Drug Submission (SNDS) | Update to labelling |
| 14253 | 2013-02-13 | New Drug Submission (NDS) | |
Request a quote for AREPANRIX H5N1
How to read a Canadian DIN record